Caribou Biosciences, Inc. (NASDAQ:CRBU) Sees Significant Increase in Short Interest

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) saw a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 9,490,000 shares, an increase of 24.4% from the April 30th total of 7,630,000 shares. Based on an average trading volume of 1,040,000 shares, the short-interest ratio is currently 9.1 days. Currently, 11.7% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 target price (down from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th.

Caribou Biosciences Trading Up 15.6%

Shares of CRBU traded up $0.17 on Friday, reaching $1.26. 2,027,432 shares of the company's stock were exchanged, compared to its average volume of 1,398,707. The stock has a market capitalization of $117.19 million, a P/E ratio of -0.76 and a beta of 2.44. The business has a 50 day moving average price of $0.89 and a two-hundred day moving average price of $1.29. Caribou Biosciences has a 12 month low of $0.66 and a 12 month high of $3.00.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43). The business had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. Equities research analysts predict that Caribou Biosciences will post -1.64 EPS for the current year.

Institutional Investors Weigh In On Caribou Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Centric Wealth Management bought a new stake in shares of Caribou Biosciences during the fourth quarter worth approximately $27,000. Russell Investments Group Ltd. increased its stake in Caribou Biosciences by 859.0% in the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock valued at $38,000 after purchasing an additional 21,416 shares in the last quarter. MetLife Investment Management LLC increased its stake in Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after purchasing an additional 9,148 shares in the last quarter. Diametric Capital LP bought a new stake in Caribou Biosciences in the fourth quarter valued at approximately $42,000. Finally, US Bancorp DE increased its stake in Caribou Biosciences by 3,524.2% in the fourth quarter. US Bancorp DE now owns 27,218 shares of the company's stock valued at $43,000 after purchasing an additional 26,467 shares in the last quarter. 77.51% of the stock is owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.